CTLA4 and neoplasm: CSF1R inhibition by PLX3397 reduces TAMs' tumor infiltration and their immunosuppressive phenotypes, potentiates ICI effects against PD-1 and CTLA4, and impairs tumor expansion by approximately 50%.